LIVE POLIO IRUS VACCINES

632 Index
Vaccine, Attenuated-continued
Type 1, CHAT (Koprowski)-continued
Philadelphia, 277, 282
serologic identification, 54
Switzerland, 322
T character and temperature variations, 57, 127
Type 1, SM (Koprowski)
six passages in man, 7
Type 1, LSc, 2ab (Sabin), 118, 302, 475
antigenic marker study, Houston strain conipared,
14
Czechoslovakia, 507
d and t characters, and monkey virulence, 34, 35
degree of stability, 58
demonstration of viremia, 371
dose and administration, Cincinnati, 592
elution behavior compared with virulent Mahoney
virus, 41-43, 46
greater concentration needed, 313
histological lesions, with no clinical signs, 92
history, 34
infant study, 294
interference and failtire, 399
Kenya, 479
New Orleans, 309
not combined with grey matter, 49
not suitable for T determinations, 132
passages in man, 7
pool possesses d- t- character, 34
Puerto Rican babies, 315
response of newborn, 302-307
spread, 592
Type 1, SM (Lederle-Cox)
antibody response in vaccinees, 539, 541
contaminant, Minnesota study, 341
Grove East, Minnesota study, 342
17% drop-outs, 554
Sottunga Island, 534
stimulated antibodies for Type 2, 197
Type 2, MEF-1 (Lederle-Cox)
disappeared and reappeared in gut, 325
Grove East, Minnesota study, 342
histological changes and markers, 33
intracerebral activity, 37
Landry-type paralysis from IS injection, 69
little genetic change after monkey passage, 76
most modified in vitro, 121
negative antibody response and concentration, 275
poor response rate, 226, 339, 375
stimulated antibodies, 197
Type 2, P-712, Ch, 2ab, (Sabin)
in infant study, 294
Philadelphia, 277, 282
Type 2, P-712, Ch, 2ab, (Sabin)
highly infectious in young infants, 313
infectivity and dose, 159
neurovirulence of vaccine and isolate, compared,
373
New Orleans, 309
passage in man, 7
predominance, 313
predominance of excretion with trivalent vaccine,
320
Type 2, P-712, Ch, 2ab, (Sabin)-continued
Puerto Rican babies, 315
young children susceptible, 257
Type 2, TN (Koprowski)
first fed to man, 5
infectivity less than other Type 2 strains, 60
passages at low temperatures, 59
ten year immunity, 8
vaccination program considered, 475
Type 3, Lederle-Fox (Lederle-Cox)
Grove East, Minnesota study, 342
interfering agent, 181
replaced paralytic strains, 198
Type 3, Leon 12, aib (Sabin)
antibody production was rare, 77
Czechoslovakia, 228
in an institution of retarded, 156
Louisiana study, 145
low immunizing capacity, 58
most infective, 152
New Orleans, 309
passage in man, 7
Puerto Rican babies, 315
T character and temperature variations, 127
undiluted form for dependable infection, 313
uniform infection, 313
unstable, 28
Type 3, Wistar-Fox (Koprowski)
in infant study, 294
Philadelphia, 277, 282
unstable, 58
Vaccine, Attcntuated, Monovalent
dose and administration, 387
dose and titer of capsuiles, 193
schedule, 368
Vaccine, Attenuated, Monovalent and Trivalent
comparison, 321, 341-354, 358, 365, 371-372, 375,
384, 444, 478, 483-484, 565, 568, 596, 602
Vaccine, Attenuated, Trivalent, 437
appearance and disappearance of individual types,
325
coexistence of types with antibody rise and no
iintoward side reaction, 198
Czechoslovakia, 507
Dade County, Florida, 44, 437
deficiency in Type 2 component, 372
dose and administration, 271, 547
evidence of intra- and interfamilial spread, 174-184.
562
in 5-month child, excretion detail, 324
Japan, field trial, 198
Minnesota study, 208
recommended, 113, 121, 341, 368
reinforcement of resistance by refeeding, 363, 410,
444, 602
related to feeding schedule, 357-364
response of immune subjects to booster, 203, 204
some reaction recognized, 574
Sottunga Island, 534
ten days before onset of polio, 571
Toluca, Mexico, 378
Type 2 component increased in Florida trials, 121